MedTrace Logo

A Study of Nivolumab in Patients With Head and Neck Cancer.

NCT04050761 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 502

Last updated 2025-07-02

No results posted yet for this study

Summary

A prospective real world evidence study of Nivolumab use in France in patient with recurrent or metastatic squamous cell carcinoma of the Head and Neck progressing on or after a platinum based therapy

Conditions

  • Squamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and Neck

Interventions

BIOLOGICAL

Nivolumab

Specified dose on Specific Days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-26
Primary Completion
2024-07-08
Completion
2024-07-08
FDA Drug
Yes

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04050761 on ClinicalTrials.gov